Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Rafik Karaman. (2014) Using predrugs to optimize drug candidates. Expert Opinion on Drug Discovery 9:12, pages 1405-1419.
Read now
Read now
Manuel Simon, Nikolas Stefan, Andreas Plückthun & Uwe Zangemeister-Wittke. (2013) Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opinion on Drug Delivery 10:4, pages 451-468.
Read now
Read now
Nikesh Gupta, Anju Shrivastava & Rakesh K Sharma. (2012) Silica nanoparticles coencapsulating gadolinium oxide and horseradish peroxidase for imaging and therapeutic applications. International Journal of Nanomedicine 7, pages 5491-5500.
Read now
Read now
Girja S Shukla & David N Krag. (2006) Selective delivery of therapeutic agents for the diagnosis and treatment of cancer. Expert Opinion on Biological Therapy 6:1, pages 39-54.
Read now
Read now
Kerry A Chester, Matthew Baker & Astrid Mayer. (2005) Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Review of Clinical Immunology 1:4, pages 549-559.
Read now
Read now
Jean-Luc Teillaud. (2005) Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges. Expert Opinion on Biological Therapy 5:sup1, pages S15-S27.
Read now
Read now
Articles from other publishers (59)
Valerio Sabatino, V.B. Unnikrishnan & Gonçalo J.L. Bernardes. (2022) Transition metal mediated bioorthogonal release. Chem Catalysis 2:1, pages 39-51.
Crossref
Crossref
Paul Cowling, Mark Bradley & Annamaria Lilienkampf. (2021) Attaching palladium catalysts to antibodies. Bioorganic & Medicinal Chemistry 44, pages 116298.
Crossref
Crossref
Claudia A. Garay-Canales, Laura Díaz-Alvarez & Georgina I. Lopez-Cortes. 2021. Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives. Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives
227
251
.
Jian Cao, Xuejiao Li & Hongqi Tian. (2020) Metal-Organic Framework (MOF)-Based Drug Delivery. Current Medicinal Chemistry 27:35, pages 5949-5969.
Crossref
Crossref
Sahar Roozbehi, Simin Dadashzadeh, Manouchehr Mirshahi, Majid Sadeghizadeh & Reza H. Sajedi. (2020) Targeted anticancer prodrug therapy using dextran mediated enzyme–antibody conjugate and β-cyclodextrin-curcumin inclusion complex. International Journal of Biological Macromolecules 160, pages 1029-1041.
Crossref
Crossref
Jun Li, Yedan Zhu, Miaohong Xie, Qian Zhang & Wenting Du. (2019) Design, synthesis, and biological evaluation of target water‐soluble hydroxamic acid‐based HDACi derivatives as prodrugs. Chemical Biology & Drug Design 94:4, pages 1760-1767.
Crossref
Crossref
Hui Gao & Gangliang Huang. (2018) Synthesis, anticancer activity and cytotoxicity of galactosylated epothilone B. Bioorganic & Medicinal Chemistry 26:20, pages 5578-5581.
Crossref
Crossref
Abhinav P. Mishra, Suresh Chandra, Ruchi Tiwari, Ashish Srivastava & Gaurav Tiwari. (2018) Therapeutic Potential of Prodrugs Towards Targeted Drug Delivery. The Open Medicinal Chemistry Journal 12:1, pages 111-123.
Crossref
Crossref
Xizhen Lian, Yanyan Huang, Yuanyuan Zhu, Yu Fang, Rui Zhao, Elizabeth Joseph, Jialuo Li, Jean-Philippe Pellois & Hong-Cai Zhou. (2018) Enzyme-MOF Nanoreactor Activates Nontoxic Paracetamol for Cancer Therapy. Angewandte Chemie International Edition 57:20, pages 5725-5730.
Crossref
Crossref
Xizhen Lian, Yanyan Huang, Yuanyuan Zhu, Yu Fang, Rui Zhao, Elizabeth Joseph, Jialuo Li, Jean-Philippe Pellois & Hong-Cai Zhou. (2018) Enzyme-MOF Nanoreactor Activates Nontoxic Paracetamol for Cancer Therapy. Angewandte Chemie 130:20, pages 5827-5832.
Crossref
Crossref
Anna Pawełczyk, Katarzyna Sowa-Kasprzak, Dorota Olender & Lucjusz Zaprutko. (2018) Molecular Consortia—Various Structural and Synthetic Concepts for More Effective Therapeutics Synthesis. International Journal of Molecular Sciences 19:4, pages 1104.
Crossref
Crossref
Qiong Wang, Cheng-Yu Chung, Julian N. Rosenberg, Geng Yu & Michael J. Betenbaugh. 2018. Recombinant Protein Expression in Mammalian Cells. Recombinant Protein Expression in Mammalian Cells
237
257
.
Surinder K. Sharma & Kenneth D. Bagshawe. (2017) Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations. Advanced Drug Delivery Reviews 118, pages 2-7.
Crossref
Crossref
Baoji Du, Dan Li, Jin Wang & Erkang Wang. (2017) Designing metal-contained enzyme mimics for prodrug activation. Advanced Drug Delivery Reviews 118, pages 78-93.
Crossref
Crossref
Monika A. Lesniewska-Kowiel & Izabela Muszalska. (2017) Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds. European Journal of Medicinal Chemistry 129, pages 53-71.
Crossref
Crossref
Dikran Sarko. (2016) Kidney-Specific Drug Delivery: Review of Opportunities, Achievements, and Challenges. Journal of Analytical & Pharmaceutical Research 2:5.
Crossref
Crossref
Karel Ulbrich, Kateřina Holá, Vladimir Šubr, Aristides Bakandritsos, Jiří Tuček & Radek Zbořil. (2016) Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. Chemical Reviews 116:9, pages 5338-5431.
Crossref
Crossref
B. Paul Morgan & Claire L. Harris. (2015) Complement, a target for therapy in inflammatory and degenerative diseases. Nature Reviews Drug Discovery 14:12, pages 857-877.
Crossref
Crossref
Yong Mi Choi-Sledeski & Camille G. Wermuth. 2015. The Practice of Medicinal Chemistry. The Practice of Medicinal Chemistry
657
696
.
Surinder K. Sharma, Kerry A. Chester & Kenneth D. Bagshawe. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
475
486
.
P. Markus Deckert. 2017. Encyclopedia of Cancer. Encyclopedia of Cancer
269
270
.
P. Markus Deckert. 2016. Encyclopedia of Cancer. Encyclopedia of Cancer
1
2
.
Stefan R. Schmidt. 2013. Fusion Protein Technologies for Biopharmaceuticals. Fusion Protein Technologies for Biopharmaceuticals
253
269
.
John Dickenson, Fiona Freeman, Chris Lloyd Mills, Shiva Sivasubramaniam & Christian Thode. 2012. Molecular Pharmacology. Molecular Pharmacology
367
380
.
Marlein Miranda Cona, Huaijun Wang, Junjie Li, Yuanbo Feng, Feng Chen, Peter de Witte, Alfons Verbruggen & Yicheng Ni. (2011) Continuing pursuit for ideal systemic anticancer radiotherapeutics. Investigational New Drugs 30:5, pages 2050-2065.
Crossref
Crossref
Mohammad H. El-Dakdouki & Paul W. Erhardt. (2012) Analogue-based drug discovery: Contributions to medicinal chemistry principles and drug design strategies. Microtubule stabilizers as a case in point (Special Topic Article). Pure and Applied Chemistry 84:7, pages 1479-1542.
Crossref
Crossref
. 2012. Therapeutic Antibody Engineering. Therapeutic Antibody Engineering
459
595
.
Anne Wadouachi & José Kovensky. (2011) Synthesis of Glycosides of Glucuronic, Galacturonic and Mannuronic Acids: An Overview. Molecules 16:5, pages 3933-3968.
Crossref
Crossref
Suzanne A. Eccles. 2011. Tumor Models in Cancer Research. Tumor Models in Cancer Research
447
495
.
Ronan O’Dwyer, Rafia Razzaque, Xuejun Hu, Susan K. Hollingshead & J. Gerard Wall. (2008) Engineering of Cysteine Residues Leads to Improved Production of a Human Dipeptidase Enzyme in E. coli. Applied Biochemistry and Biotechnology 159:1, pages 178-190.
Crossref
Crossref
Gairin Dancey, Richard H. Begent & Tim Meyer. (2009) Imaging in targeted delivery of therapy to cancer. Targeted Oncology 4:3, pages 201-217.
Crossref
Crossref
V. P. Baklaushev, K. A. Pavlov & V. P. Chekhonin. (2009) Monoclonal antibodies in diagnostics of high-grade gliomas. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry 3:2, pages 105-115.
Crossref
Crossref
Guozheng Liu & Donald J. Hnatowich. (2008) A Semiempirical Model of Tumor Pretargeting. Bioconjugate Chemistry 19:11, pages 2095-2104.
Crossref
Crossref
Mickaël Thomas, Jonathan Clarhaut, Isabelle Tranoy-Opalinski, Jean-Pierre Gesson, Joëlle Roche & Sébastien Papot. (2008) Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy. Bioorganic & Medicinal Chemistry 16:17, pages 8109-8116.
Crossref
Crossref
Greg M. Thurber, Michael M. Schmidt & K. Dane Wittrup. (2008) Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Advanced Drug Delivery Reviews 60:12, pages 1421-1434.
Crossref
Crossref
Jarkko Rautio, Hanna Kumpulainen, Tycho Heimbach, Reza Oliyai, Dooman Oh, Tomi Järvinen & Jouko Savolainen. (2008) Prodrugs: design and clinical applications. Nature Reviews Drug Discovery 7:3, pages 255-270.
Crossref
Crossref
Dragan Grabulovski & Dario Neri. 2008. Tumor Angiogenesis. Tumor Angiogenesis
491
509
.
Hossein Borghaei, Liat Binyamin, Igor Astsaturov & Louis M. Weiner. 2008. Molecular Targeting in Oncology. Molecular Targeting in Oncology
371
412
.
Eveline Trachsel, Manuela Kaspar, Frank Bootz, Michael Detmar & Dario Neri. (2007) A Human mAb Specific to Oncofetal Fibronectin Selectively Targets Chronic Skin Inflammation In Vivo. Journal of Investigative Dermatology 127:4, pages 881-886.
Crossref
Crossref
Sunny Abraham, Fang Guo, Lian-Sheng Li, Christoph Rader, Cheng Liu, Carlos F. BarbasIIIIII, Richard A. Lerner & Subhash C. Sinha. (2007) Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation. Proceedings of the National Academy of Sciences 104:13, pages 5584-5589.
Crossref
Crossref
Stefan Dübel. (2007) Recombinant therapeutic antibodies. Applied Microbiology and Biotechnology 74:4, pages 723-729.
Crossref
Crossref
Mickaël Thomas, Freddy Rivault, Isabelle Tranoy-Opalinski, Joëlle Roche, Jean-Pierre Gesson & Sébastien Papot. (2007) Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) β-glucuronide and β-galactoside for application in selective prodrug chemotherapy. Bioorganic & Medicinal Chemistry Letters 17:4, pages 983-986.
Crossref
Crossref
Qing Zhang, Si-He Zhang, Ming-Quan Su, Guo-Qiang Bao, Jia-Yun Liu, Jing Yi, Jian-Jun Shen & Xiao-Ke Hao. (2006) Guided selection of an anti-gamma-seminoprotein human Fab for antibody directed enzyme prodrug therapy of prostate cancer. Cancer Immunology, Immunotherapy 56:4, pages 477-489.
Crossref
Crossref
Surinder K. Sharma, Kerry A. Chester & Kenneth D. Bagshawe. 2007. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
501
513
.
Susanna M. Rybak & Dianne L. Newton. 2007. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
379
410
.
Christoph Rader & Michael R. Bishop. 2007. General Principles of Tumor Immunotherapy. General Principles of Tumor Immunotherapy
453
484
.
Kenneth D. Bagshawe. 2007. Prodrugs. Prodrugs
525
540
.
Jean-Claude Florent & Claude Monneret. 2008. Anthracycline Chemistry and Biology II. Anthracycline Chemistry and Biology II
99
140
.
Abdessamad El Alaoui, Frédéric Schmidt, Claude Monneret & Jean-Claude Florent. (2006) Protecting Groups for Glucuronic Acid: Application to the Synthesis of New Paclitaxel (Taxol) Derivatives. The Journal of Organic Chemistry 71:26, pages 9628-9636.
Crossref
Crossref
Mariusz Skwarczynski, Yoshio Hayashi & Yoshiaki Kiso. (2006) Paclitaxel Prodrugs: Toward Smarter Delivery of Anticancer Agents. Journal of Medicinal Chemistry 49:25, pages 7253-7269.
Crossref
Crossref
Q.i. Zhang, Guangya Xiang, Youjiu Zhang, Keya Yang, W.o. Fan, Jialiang Lin, Fanbo Zeng & Jizhou Wu. (2006) Increase of doxorubicin sensitivity for folate receptor positive cells when given as the prodrug N‐(phenylacetyl) doxorubicin in combination with folate‐conjugated PGA. Journal of Pharmaceutical Sciences 95:10, pages 2266-2275.
Crossref
Crossref
Yingjuan Lu, Jun Yang & Emanuela Sega. (2006) Issues related to targeted delivery of proteins and peptides. The AAPS Journal 8:3, pages E466-E478.
Crossref
Crossref
Eveline Trachsel & Dario Neri. (2006) Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis. Advanced Drug Delivery Reviews 58:5-6, pages 735-754.
Crossref
Crossref
G. Egri & A. Takáts. (2006) Monoclonal antibodies in the treatment of lung cancer. European Journal of Surgical Oncology (EJSO) 32:4, pages 385-394.
Crossref
Crossref
David M. Goldenberg, Robert M. Sharkey, Giovanni Paganelli, Jacques Barbet & Jean-François Chatal. (2006) Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy. Journal of Clinical Oncology 24:5, pages 823-834.
Crossref
Crossref
George L. Mayers. (2006) Targeted molecular brachytherapy. Drug Development Research 67:1, pages 94-106.
Crossref
Crossref
Christopher J. Sunderland, Matthias Steiert, James E. Talmadge, Austin M. Derfus & Stephen E. Barry. (2006) Targeted nanoparticles for detecting and treating cancer. Drug Development Research 67:1, pages 70-93.
Crossref
Crossref
Fiona A. Harding, Amy D. Liu, Marcia Stickler, O. Jennifer Razo, Regina Chin, Nargol Faravashi, Wendy Viola, Tom Graycar, V. Pete Yeung, Wolfgang Aehle, Daan Meijer, Stephanie Wong, M. Harunur Rashid, Ana M. Valdes & Volker Schellenberger. (2005) A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Molecular Cancer Therapeutics 4:11, pages 1791-1800.
Crossref
Crossref
Robert M. Sharkey, Habibe Karacay, Thomas M. Cardillo, Chien-Hsing Chang, William J. McBride, Edmund A. Rossi, Ivan D. Horak & David M. Goldenberg. (2005) Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods. Clinical Cancer Research 11:19, pages 7109s-7121s.
Crossref
Crossref